These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

93 related articles for article (PubMed ID: 21570311)

  • 1. Studies for the application of boron neutron capture therapy to the treatment of differentiated thyroid cancer.
    Dagrosa A; Carpano M; Perona M; Thomasz L; Nievas S; Cabrini R; Juvenal G; Pisarev M
    Appl Radiat Isot; 2011 Dec; 69(12):1752-5. PubMed ID: 21570311
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Biodistribution of boron compounds in an animal model of human undifferentiated thyroid cancer for boron neutron capture therapy.
    Dagrosa MA; Viaggi M; Rebagliati RJ; Batistoni D; Kahl SB; Juvenal GJ; Pisarev MA
    Mol Pharm; 2005; 2(2):151-6. PubMed ID: 15804189
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Boron neutron capture therapy applied to undifferentiated thyroid carcinoma].
    Pisarev MA; Dagrosa MA; Thomasz L; Juvenal G
    Medicina (B Aires); 2006; 66(6):569-73. PubMed ID: 17240633
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Boron neutron capture therapy for undifferentiated thyroid carcinoma: preliminary results with the combined use of BPA and BOPP.
    Viaggi M; Dagrosa MA; Longhino J; Blaumann H; Calzetta O; Kahl SB; Juvenal GJ; Pisarev MA
    Appl Radiat Isot; 2004 Nov; 61(5):905-9. PubMed ID: 15308166
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Optimization of boron neutron capture therapy for the treatment of undifferentiated thyroid cancer.
    Dagrosa MA; Thomasz L; Longhino J; Perona M; Calzetta O; Blaumann H; Rebagliati RJ; Cabrini R; Kahl S; Juvenal GJ; Pisarev MA
    Int J Radiat Oncol Biol Phys; 2007 Nov; 69(4):1059-66. PubMed ID: 17967301
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Selective uptake of p-borophenylalanine by undifferentiated thyroid carcinoma for boron neutron capture therapy.
    Dagrosa MA; Viaggi M; Kreimann E; Farías S; Garavaglia R; Agote M; Cabrini RL; Dadino JL; Juvenal GJ; Pisarev MA
    Thyroid; 2002 Jan; 12(1):7-12. PubMed ID: 11838734
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Biodistribution of p-borophenylalanine (BPA) in dogs with spontaneous undifferentiated thyroid carcinoma (UTC).
    Dagrosa MA; Viaggi M; Rebagliati RJ; Castillo VA; Batistoni D; Cabrini RL; Castiglia S; Juvenal GJ; Pisarev MA
    Appl Radiat Isot; 2004 Nov; 61(5):911-5. PubMed ID: 15308167
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Delivery of (10)boron to oral squamous cell carcinoma using boronophenylalanine and borocaptate sodium for boron neutron capture therapy.
    Obayashi S; Kato I; Ono K; Masunaga S; Suzuki M; Nagata K; Sakurai Y; Yura Y
    Oral Oncol; 2004 May; 40(5):474-82. PubMed ID: 15006618
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Boron neutron capture therapy for clear cell sarcoma (CCS): biodistribution study of p-borono-L-phenylalanine in CCS-bearing animal models.
    Andoh T; Fujimoto T; Sudo T; Fujita I; Imabori M; Moritake H; Sugimoto T; Sakuma Y; Takeuchi T; Kawabata S; Kirihata M; Akisue T; Yayama K; Kurosaka M; Miyatake S; Fukumori Y; Ichikawa H
    Appl Radiat Isot; 2011 Dec; 69(12):1721-4. PubMed ID: 21367607
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of boron neutron capture therapy on human oral squamous cell carcinoma in a nude mouse model.
    Kamida A; Obayashi S; Kato I; Ono K; Suzuki M; Nagata K; Sakurai Y; Yura Y
    Int J Radiat Biol; 2006 Jan; 82(1):21-9. PubMed ID: 16546900
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Experimental Studies of Boronophenylalanine ((10)BPA) Biodistribution for the Individual Application of Boron Neutron Capture Therapy (BNCT) for Malignant Melanoma Treatment.
    Carpano M; Perona M; Rodriguez C; Nievas S; Olivera M; Santa Cruz GA; Brandizzi D; Cabrini R; Pisarev M; Juvenal GJ; Dagrosa MA
    Int J Radiat Oncol Biol Phys; 2015 Oct; 93(2):344-52. PubMed ID: 26232853
    [TBL] [Abstract][Full Text] [Related]  

  • 12. In vitro and in vivo evaluation of o-carboranylalanine as a potential boron delivery agent for neutron capture therapy.
    Yong JH; Barth RF; Wyzlic IM; Soloway AH; Rotaru JH
    Anticancer Res; 1995; 15(5B):2033-8. PubMed ID: 8572598
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Suitability of boron carriers for BNCT: accumulation of boron in malignant and normal liver cells after treatment with BPA, BSH and BA.
    Chou FI; Chung HP; Liu HM; Chi CW; Lui WY
    Appl Radiat Isot; 2009 Jul; 67(7-8 Suppl):S105-8. PubMed ID: 19375330
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Boron neutron capture therapy in cancer: past, present and future.
    Pisarev MA; Dagrosa MA; Juvenal GJ
    Arq Bras Endocrinol Metabol; 2007 Jul; 51(5):852-6. PubMed ID: 17891250
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The hamster cheek pouch as a model of oral cancer for boron neutron capture therapy studies: selective delivery of boron by boronophenylalanine.
    Kreimann EL; Itoiz ME; Dagrosa A; Garavaglia R; Farías S; Batistoni D; Schwint AE
    Cancer Res; 2001 Dec; 61(24):8775-81. PubMed ID: 11751398
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evaluation of BPA uptake in clear cell sarcoma (CCS) in vitro and development of an in vivo model of CCS for BNCT studies.
    Fujimoto T; Andoh T; Sudo T; Fujita I; Imabori M; Moritake H; Sugimoto T; Sakuma Y; Takeuchi T; Sonobe H; Epstein AL; Akisue T; Kirihata M; Kurosaka M; Fukumori Y; Ichikawa H
    Appl Radiat Isot; 2011 Dec; 69(12):1713-6. PubMed ID: 21354804
    [TBL] [Abstract][Full Text] [Related]  

  • 17. In vitro neutron irradiation of glioma and endothelial cultured cells.
    Menichetti L; Gaetano L; Zampolli A; Del Turco S; Ferrari C; Bortolussi S; Stella S; Altieri S; Salvadori PA; Cionini L
    Appl Radiat Isot; 2009 Jul; 67(7-8 Suppl):S336-40. PubMed ID: 19410472
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Improvement of the boron neutron capture therapy (BNCT) by the previous administration of the histone deacetylase inhibitor sodium butyrate for the treatment of thyroid carcinoma.
    Perona M; Rodríguez C; Carpano M; Thomasz L; Nievas S; Olivera M; Thorp S; Curotto P; Pozzi E; Kahl S; Pisarev M; Juvenal G; Dagrosa A
    Radiat Environ Biophys; 2013 Aug; 52(3):363-73. PubMed ID: 23636505
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Boron-containing nucleosides as potential delivery agents for neutron capture therapy of brain tumors.
    Barth RF; Yang W; Al-Madhoun AS; Johnsamuel J; Byun Y; Chandra S; Smith DR; Tjarks W; Eriksson S
    Cancer Res; 2004 Sep; 64(17):6287-95. PubMed ID: 15342417
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Boron delivery for boron neutron capture therapy targeting a cancer-upregulated oligopeptide transporter.
    Miyabe J; Ohgaki R; Saito K; Wei L; Quan L; Jin C; Liu X; Okuda S; Nagamori S; Ohki H; Yoshino K; Inohara H; Kanai Y
    J Pharmacol Sci; 2019 Mar; 139(3):215-222. PubMed ID: 30833090
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.